Durata Therapeutics Completes Target Enrollment in Phase 3 DISCOVER 2 Clinical Trial Comparing Dalbavancin to Vancomycin and Linezolid in ABSSSI Patients

Download PDF

Milestone Achieved On Schedule, NDA Filing on Track for Q2 2013

MORRISTOWN, N.J.--(BUSINESS WIRE)--Durata Therapeutics (NASDAQ: DRTX) today announced that it has completed its target enrollment for DISCOVER 2 (“Dalbavancin for Infections of the Skin COmpared to Vancomycin at an Early Response”), the second global, Phase 3 clinical trial of Durata’s lead product candidate, dalbavancin, under investigation for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible gram-positive bacteria.

DISCOVER 2 is a randomized, double-blind, double-dummy trial comparing the efficacy of dalbavancin to a regimen of vancomycin for the treatment of ABSSSI. Researchers are comparing two intravenous doses of dalbavancin given one week apart with twice daily vancomycin doses for 14 days. Patients randomized to the vancomycin regimen have an option to switch to oral linezolid after three days of vancomycin treatment.

As with DISCOVER 1, the protocol design of DISCOVER 2 is consistent with FDA’s Draft Guidance for Developing Drugs for Treatment of ABSSSI. This pivotal study is being conducted pursuant to a special protocol agreement with the U.S. Food and Drug Administration, and is also designed based on scientific advice provided by the European Medicines Agency (EMA).

“With the completion of patient enrollment for our DISCOVER 2 pivotal trial on schedule, we believe we are on track for submitting our New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in the first half of 2013,” said Durata Chief Executive Officer Paul R. Edick.

The primary outcome measure of DISCOVER 2 is a comparison of clinical response to therapy measured 48-72 hours after initiation of therapy determined by the cessation of spread of the erythema (redness) associated with the lesion, as well as the resolution of fever. The study, at 139 sites in the United States, Europe, Asia and South Africa, targeted enrollment of 740 patients.

Additional information regarding the trial can be found on clinicaltrials.gov.

About Dalbavancin

Dalbavancin is an intravenous antibiotic product candidate under investigation for once-weekly dosing, which we believe may facilitate the treatment of patients with ABSSSI in both the in-patient and out-patient settings, potentially reducing the length of a patient’s hospital stay or avoiding hospital admission altogether, with an impact on the overall cost of care for these patients.

About Durata Therapeutics

Durata Therapeutics is a pharmaceutical company focused on the development and commercialization of novel therapeutics for patients with infectious diseases and acute illnesses. Durata has completed enrollment in two global Phase 3 clinical trials with its lead product candidate, dalbavancin, for the treatment of patients with acute bacterial skin and skin structure infections, or ABSSSI.

Forward-looking statements

Statements contained in this press release contain forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this press release, including statements regarding our strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management, are forward-looking statements. The words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements in this press release include statements about the timing of the filing of a New Drug Application with the U.S. Food and Drug Administration. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those discussed in the “Risk Factors” section of our most recent quarterly report on Form 10-Q, which is on file with the SEC and is also available on our website. In addition, any forward-looking statements represent our views only as of today and should not be relied upon as representing our views as of any subsequent date. While we may elect to update these forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, even if our views change. Therefore, you should not rely on these forward-looking statements as representing our views as of any date subsequent to today.

Contacts

Investor Relations and Public Affairs Contact
Durata Therapeutics
Allison Wey
Vice President, Investor Relations and Public Affairs
(312) 612-5462
awey@duratatherapeutics.com
or
Media Relations Contacts
White Oak Communications, Inc.
Jed Weiner
(847) 392-4186
jed.weiner@comcast.net
or
Durata Therapeutics
Allison Wey
Vice President, Investor Relations and Public Affairs
(312) 612-5462
awey@duratatherapeutics.com